VALIRX PLC – Conclusion Of Evaluation With University Of Dundee
RNS Number : 1731J ValiRx PLC 22 June 2026 22 June 2026 ValiRx PLC (“ValiRx” or the “Company”)
RNS Number : 1731J ValiRx PLC 22 June 2026 22 June 2026 ValiRx PLC (“ValiRx” or the “Company”)
RNS Number : 1818J ValiRx PLC 22 June 2026 ValiRx PLC (“ValiRx” or the “Company”) Final Results
London, UK, 1 July 2020: ValiRx (AIM:VAL) , the clinical stage biotechnology company today announces its final results for the year ended 31 December 2019.
London, UK., 26 September 2019: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialisation and partnering, today announces its Half Yearly Report for the period ended 30 June 2019 and provides an update e on significant post-period events.
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company’s clinical team has signed an agreement to work with Aptus Clinical Ltd (“Aptus”), the UK based, clinical Contract Research Organisation, to effectuate a clinical development plan for VAL301 incorporating a Phase I/II study design concept in Endometriosis.
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides an update on its therapeutic drugs, VAL201 and its current clinical status.
ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, today announces its final results for the year ended 31 December 2018.
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces acquisition of IP and JV.
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides the following update on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401.
ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel